Business news for the stock market
Leverkusen, Germany (pta020/25.08.2022/10:30) - Biofrontera AG (FSE: B8F, US-OTC: BFAGY), an international biopharmaceutical company, announces the election of Prof. Dr. Karin Lergenmüller to the Supervisory Board at the Annual General Meeting on August 23, 2022. The attending shareholders represented approximately 46% of the registered share capital.
Following Prof. Dr. Ruhwedel's resignation from the Supervisory Board in February 2022, a sixth position on the Supervisory Board of Biofrontera AG was temporarily vacant. The management submitted a proposed resolution to Annual General Meeting to downsize the Supervisory Board to five members, which was, however, rejected by the shareholders.
The appointment of Prof. Lergenmüller to the Supervisory Board of Biofrontera AG, as proposed by Deutsche Balaton AG by way of a supplementary motion, was approved by a majority of 73.6% of the share capital permitted to be represented at the Annual General Meeting.
Prof. Lergenmüller worked for Deutsche Bank AG after holding positions in the management consulting industry, including at Andersen Consulting and Gemini Consulting. From 1996 to 1998 she was a member of the management of Joas & Comp., Bad Homburg. Since 1999, Prof. Dr. Karin Lergenmüller has been Professor of Marketing and General Business Administration at the Rhine-Main University of Applied Sciences, Wiesbaden. Since 2000 Prof. Dr. Karin Lergenmüller is Global Equity Investor, specialized in Digital World, Technology companies, NFT's and Crypto. Furthermore, Prof. Lergenmüller holds various supervisory board mandates in companies of the Deutsche Balaton Group.
The Annual General Meeting of Biofrontera AG was again held in virtual format and without the physical presence of the shareholders or their proxies. Further information on the Annual General Meeting, including the detailed voting results and the Management Board presentation, can be found at: https://www.biofrontera.com/de/hauptversammlung.html.
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com
Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "predict", "estimate" and "intend", among others. Such forward-looking statements are based on current estimates and assumptions made by Biofrontera AG's management to the best of its knowledge and belief, which in their opinion are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the company or industry to be materially different from any future results, financial condition, performance or achievements expressed or implied by such forward-looking statements. No undue reliance should be placed on such statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements.
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC